Company Contact:
Legal Entity Type: C-Corp
Company Type: Biotechnology
Company Stage: Development
No. of Employees: 6
Desired Financial Amount: The financial planning schedule for funding rounds is the following: Seed Funding Year 1: $2.45M Seed funding for non-GLP toxicity study (1 large rodent species) Series A Funding Year 2: $13.5M Series A funding for CMC activities + GLP tox studies (2 large animal species) Series B Funding Year 3: $15.42M Series B funding for FIH clinical trial Phase 1 safety study